J Okla State Med Assoc 2003,96(5):214–217 PubMed 7 CDC: Laborato

J Okla State Med Assoc 2003,96(5):214–217.PubMed 7. CDC: Laboratory-acquired human glanders. 49 MMWr: CDC 2000, 532–535. 8. Kenny DJ, Russell P, Rogers D, Eley SM, Titball

RW: In vitro susceptibilities of Burkholderia mallei in comparison to those of other pathogenic Burkholderia spp. Antimicrob Agents Chemother 1999,43(11):2773–2775.PubMed 9. Heine HS, England MJ, Waag DM, Byrne this website WR: In vitro antibiotic susceptibilities of Burkholderia mallei (causative agent of glanders) determined by broth microdilution and E-test. Antimicrob Agents Chemother 2001,45(7):2119–2121.CrossRefPubMed 10. Dance DA, Wuthiekanun V, Chaowagul W, White NJ: The antimicrobial susceptibility of Pseudomonas pseudomallei. Emergence of resistance in vitro and during treatment. J Antimicrob Chemother 1989,24(3):295–309.CrossRefPubMed 11. Chaowagul W, Suputtamongkul Y, Smith MD, White NJ: Oral fluoroquinolones for maintenance treatment of melioidosis. Trans R Soc Trop Med Hyg 1997,91(5):599–601.CrossRefPubMed https://www.selleckchem.com/products/sn-38.html 12. Whitlock GC, Estes DM, Young GM, Young B, Torres AG: Construction of a reporter system to study Burkholderia mallei type III secretion and identification of the BopA effector protein function in intracellular survival. Trans R Soc Trop Med Hyg 2008,102(Suppl 1):S127–133.CrossRefPubMed 13. Ribot WJ, Ulrich RL: The animal pathogen-like type III secretion system is required for the intracellular

survival of Burkholderia mallei within J774.2 macrophages. Infect Immun 2006,74(7):4349–4353.CrossRefPubMed 14. White NJ, Dance DA, Chaowagul W, Wattanagoon Y, Wuthiekanun V, Pitakwatchara N: Halving

of mortality of severe melioidosis by ceftazidime. Lancet 1989,2(8665):697–701.CrossRefPubMed 15. Thibault FM, Hernandez E, Vidal DR, Girardet M, Cavallo JD: Antibiotic susceptibility Avelestat (AZD9668) of 65 isolates of Burkholderia pseudomallei and Burkholderia mallei to 35 antimicrobial agents. J Antimicrob Chemother 2004,54(6):1134–1138.CrossRefPubMed 16. Inglis TJ, Rodrigues F, Rigby P, Norton R, Currie BJ: Comparison of the susceptibilities of Burkholderia pseudomallei to meropenem and ceftazidime by conventional and intracellular methods. Antimicrob Agents Chemother 2004,48(8):2999–3005.CrossRefPubMed 17. Karunakaran R, Puthucheary SD: Burkholderia pseudomallei: in vitro susceptibility to some new and old antimicrobials. Scand J Infect Dis 2007,39(10):858–861.CrossRefPubMed 18. Lopez J, Copps J, Wilhelmsen C, Moore R, Kubay J, St-Jacques M, Halayko S, Kranendonk C, Toback S, DeShazer D, et al.: Characterization of experimental equine glanders. Microbes Infect 2003,5(12):1125–1131.CrossRefPubMed 19. Howe C: Glanders. The Oxford medicine (Edited by: C H). New York: Oxford University Press 1949, 185–201. 20. Fritz DL, Vogel P, Brown DR, Deshazer D, Waag DM: Mouse model of sublethal and lethal intraperitoneal glanders (Burkholderia mallei). Vet Pathol 2000,37(6):626–636.CrossRefPubMed 21.

Comments are closed.